CN101791287A - Solid oral drug composite containing aripiprazole microcrystalline - Google Patents
Solid oral drug composite containing aripiprazole microcrystalline Download PDFInfo
- Publication number
- CN101791287A CN101791287A CN 201010119171 CN201010119171A CN101791287A CN 101791287 A CN101791287 A CN 101791287A CN 201010119171 CN201010119171 CN 201010119171 CN 201010119171 A CN201010119171 A CN 201010119171A CN 101791287 A CN101791287 A CN 101791287A
- Authority
- CN
- China
- Prior art keywords
- aripiprazole
- type
- lactose
- compositions
- starch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 229960004372 aripiprazole Drugs 0.000 title claims abstract description 67
- 229940126701 oral medication Drugs 0.000 title abstract description 8
- 239000007787 solid Substances 0.000 title abstract description 4
- 239000002131 composite material Substances 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 claims description 41
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 20
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 20
- 239000008101 lactose Substances 0.000 claims description 20
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 20
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 20
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 20
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 16
- 239000011734 sodium Substances 0.000 claims description 16
- 229910052708 sodium Inorganic materials 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 229920002472 Starch Polymers 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 8
- 239000007909 solid dosage form Substances 0.000 claims description 8
- 239000008119 colloidal silica Substances 0.000 claims description 7
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 7
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 7
- 229920003081 Povidone K 30 Polymers 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229960003943 hypromellose Drugs 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 17
- 239000013078 crystal Substances 0.000 abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 201000000980 schizophrenia Diseases 0.000 abstract description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 229950005770 hyprolose Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940117389 dichlorobenzene Drugs 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- UXQBDXJXIVDBTF-UHFFFAOYSA-N 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1h-quinolin-2-one;hydrate Chemical compound O.ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl UXQBDXJXIVDBTF-UHFFFAOYSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940029131 aripiprazole 10 mg Drugs 0.000 description 1
- 229940029120 aripiprazole 15 mg Drugs 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- IAZVVHPXBDEBOY-UHFFFAOYSA-L disodium dodecyl sulfate acetate Chemical compound C(C)(=O)[O-].[Na+].S(=O)(=O)(OCCCCCCCCCCCC)[O-].[Na+] IAZVVHPXBDEBOY-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a solid oral drug composite containing aripiprazole microcrystalline, containing 1-50mg of aripiprazole I type crystal and pharmaceutical excipients acceptable in pharmacy; wherein the mean grain size of the aripiprazole I type crystal is no more than 50mum. The aripiprazole dissolution of the composite is obviously improved, the bioavailability and curative effect of the aripiprazole composite are improved, and the solid oral drug composite is used for treating mental diseases such as schizophrenia and the like.
Description
The application is dividing an application of patent application " a kind of Peroral solid dosage form pharmaceutical composition that contains aripiprazole crystallite " (application number being 200710041323.5, and the applying date is on May 28th, 2007).
Technical field
The invention belongs to formulation art, be specifically related to a kind of Peroral solid dosage form pharmaceutical composition that contains aripiprazole crystallite, contain brilliant 1-50mg of Aripiprazole I type and pharmaceutically acceptable pharmaceutic adjuvant, it is characterized in that: the mean diameter of Aripiprazole I type crystalline substance is no more than 50um.The Aripiprazole dissolution of the present composition is improved significantly, and can improve the bioavailability and the curative effect of Aripiprazole.
Background technology
Aripiprazole is a kind of schizoid atypical chlorpromazine that is used for the treatment of, and goes on the market in the whole world.Its chemistry 7-{4-[4-(2, the 3-Dichlorobenzene base) by name-1-piperazinyl]-butoxy }-3,4-dihydro-quinolone or 7-{4-[4-(2, the 3-Dichlorobenzene base)-1-piperazinyl]-butoxy }-3,4-2 (1H)-quinolinones.
Aripiprazole is a kind of insoluble medicine, when it is made oral formulations such as tablet or other and comprises the solid preparation of quick fusing prescription, its size has bigger influence to its active bio availability, existing bibliographical information is made micron order with the crystal formation of Aripiprazole, apply for a patent the particle diameter that CN02801754 discloses A type crystalline substance and Type B crystalline substance as China, mean diameter is 50,40,35,25,20um, China applies for a patent CN200480031386.7 and discloses a kind of compositions that contains the Aripiprazole monohydrate, its mean diameter is 25-100um, be used for injection, Chinese patent CN200480030814 discloses a kind of preparation method for preparing the aripiprazole crystal form microgranule, the mean diameter of the aripiprazole crystal form that this method obtains is 1-25um, can be used for doing oral formulations, compositionss such as injection, the mean diameter of lyophilized formulations are 2.5um.China applies for a patent particle diameter that CN200480041610 discloses a kind of II type crystalline substance (the X diffraction is different with the II type of big tomb company) for less than 300um, and WO200735348 discloses a kind of nanoscale Aripiprazole compositions, and its particle diameter is below 2um.WO200697344 (Holland) discloses a kind of pharmaceutical composition that contains the brilliant 1-5mg of Aripiprazole II type, and wherein II type crystal grain directly is distributed as 50um or accounts for 90% more for a short time.
But the fine particle (micron order) of disclosed Aripiprazole I type crystalline substance does not also have bibliographical information in Japan and Korea S's analytical chemistry annual meeting, discover through the present invention, dissolution in vitro by the I type wafer of CN02801754 disclosed method preparation was lower than 70% in 45 minutes, its bioavailability is lower, therefore, be necessary to make the preparation of particle diameter below 100um, to improve its bioavailability, therefore the present invention finishes.
Summary of the invention
The invention provides a kind of combination of oral medication of high bioavailability, contain brilliant 1-50mg of Aripiprazole I type and acceptable accessories, it is characterized in that the mean diameter of Aripiprazole I type crystalline substance is no more than 50um, preferably be no more than 35um.
Described compositions of the present invention is characterized in that the particle size distribution 90% of Aripiprazole I type crystalline substance is not more than 50um.
Above-mentioned said combination of oral medication, said pharmaceutic adjuvant are selected from one or more in following: diluent, disintegrating agent, binding agent and lubricant; Said diluent is selected from the following material one or more: lactose, microcrystalline Cellulose, starch and mannitol, and when compositions is tablet, preferred lactose and microcrystalline Cellulose, its consumption in tablet accounts for 80～95% of composition weight; Said disintegrating agent is selected from the following material one or more: carboxymethylstach sodium, polyvinylpolypyrrolidone and low-substituted hydroxypropyl cellulose, and its consumption accounts for 1～15% of composition weight; Said binding agent is a hypromellose, and polyvidone and starch slurry are an amount of; Said lubricant is magnesium stearate, sodium stearyl fumarate, Pulvis Talci, colloidal silica or their mixture, and its consumption accounts for 0.1～5% of composition weight.
Also can add correctives, as selecting artificial or natural sweeteners such as stevioside, maltose alcohol, A Siba be sweet.
The said combination of oral medication of the present invention, its dosage form are tablet, capsule or oral liquid, preferred tablet or capsule.
Compositions of the present invention, especially tablet and capsule, dissolution height, uniform content are stablized, bioavailability is high.
Aripiprazole I type crystalline substance in the compositions of the present invention, its powder X-ray-diffracting spectrum (cuK α source,
) 2 θ have characteristic peak about following value: 11.1,14.4,16.6,19.5,20.4 and 22.1, see Fig. 1; The scanning of its differential heat has been located endothermic peak (heating rate: 10 ℃/min) about 140.2 ℃.
Combination of oral medication of the present invention can prepare by following method:
The preparation method of applying for a patent the CN03135380.8 description by China makes the Aripiprazole crude product, under the mixed solvent high-speed stirred state of this crude product with ethanol or ethanol and other non-alcohols solvent formation, add water at low temperature recrystallization Aripiprazole, filter, dry, acquisition mean diameter is less than or equal to 50um Aripiprazole I type crystalline substance; This I type crystalline substance is mixed with pharmaceutic adjuvant, and the dress capsule is made capsule, maybe this I type crystalline substance is made granule with the pharmaceutic adjuvant mixing granulation, obtains tablet through tabletting.
Combination of oral medication of the present invention contains Aripiprazole 1-50mg, preferred 2.5mg, 5mg, 10mg, 15mg, 20mg, 25mg, or 30mg, more preferably 5mg, 10mg and 15mg.
The said tablet of the present invention comprises ordinary tablet, oral cavity disintegration tablet, chews sheet, effervescent tablet, buccal tablet etc. that its preparation makes by the conventional technology of preparing of the known corresponding tablet of those skilled in the art.
The dissolution of the aripiprazole crystallite Peroral solid dosage form pharmaceutical composition that the present invention obtains obviously improves, especially when compositions is tablet, when diluent is that lactose and microcrystalline Cellulose and its content are 80-95% (sheet is heavy), be equipped with other pharmaceutic adjuvant, effect is particularly outstanding, can improve the bioavailability and the curative effect of aripiprazole formulations.
Pharmaceutical composition of the present invention is used for the treatment of mental sickness such as schizophrenia, bipolar mania and depression etc.
Description of drawings
Fig. 1 is at the powder X-ray-diffracting spectrum of the Aripiprazole I of 25 ℃ of mensuration type crystalline substance
The specific embodiment
Embodiments of the invention are used for further explaining the present invention, but not the limiting protecting scope in this.
Ginseng
RatioEmbodiment
Macrocrystalline of Aripiprazole I type:
The method of applying for a patent the reference enforcement 2 of CN02801754 by China makes Aripiprazole I type crystalline substance (coarse-grain).
Prescription: (prescription is with reference to CN02801754 embodiment 22)
Aripiprazole (I type coarse-grain) 15g
Lactose 57g
Starch 10g
Microcrystalline Cellulose 10g
Hyprolose 2g
Magnesium stearate 0.9g
94.9g 1000
Preparation technology: Aripiprazole I type coarse-grain is crossed 80 mesh sieves,, add hyprolose liquid, mixing granulation with starch, lactose and microcrystalline cellulose mix homogeneously, oven dry is sieved, and adds magnesium stearate then, mix, use the tablet machine tabletting, be pressed into every tablet of tablet that contains Aripiprazole 15mg.
Embodiment 1
The preparation of Aripiprazole I type crystallite
20g Aripiprazole crude product and the adding of 240ml ethanol are taken back in three mouthfuls of reaction bulbs of flow condenser, be heated to backflow under stirring, treat to stop after Aripiprazole dissolves fully heating, line transfer speed to 500 meter/minute adds 1 ℃ water at low temperature 37ml simultaneously, with the mixture of ice and water 30min that lowers the temperature rapidly, sucking filtration, washing obtains crystallization in 80 ℃ of exsiccators with institute, and drying under reduced pressure obtained powdery aripiprazole crystals 19.2g in 10 hours.By being dispersant with water, measure its volume average particle size 26.456um with Mastersizer 2000 laser particle analyzers.
Embodiment 2
Aripiprazole I type microwafer (except that I type crystallite, prescription is with reference embodiment, and the crystallite method for making is seen embodiment)
Prescription:
Aripiprazole (I type crystallite) 15g
Lactose 57g
Starch 10g
Microcrystalline Cellulose 10g
Hyprolose 2g
Magnesium stearate 0.9g
94.9g 1000
Preparation technology: with reference embodiment.
Embodiment 3
Aripiprazole I type microwafer
Prescription
Aripiprazole (I type crystallite) 5g
Lactose 75g
Microcrystalline Cellulose 11g
Carboxymethylstach sodium 2.8g
Hypromellose 2.2g
Carboxymethylstach sodium (adding) 3.2g
Magnesium stearate 0.8g
1000 of 100g
Preparation: with Aripiprazole I type crystallite, sodium carboxymethylstarch, microcrystalline Cellulose, starch and lactose mix homogeneously, add hydroxypropyl first fiber dilute alcohol solution, mix pelletize, oven dry is sieved, and adds carboxymethyl starch sodium, mixing again, add magnesium stearate then, mix homogeneously, tabletting.
Embodiment 4
Aripiprazole I type microwafer
Prescription
Aripiprazole (I type crystallite) 10g
Lactose 70g
Microcrystalline Cellulose 28g
Carboxymethylstach sodium 3g
30 POVIDONE K 30 BP/USP-30 2.5g
Polyvinylpolypyrrolidone 2g
Sodium stearyl fumarate 1g
Pulvis Talci 3.5g
1000 of 120g
Preparation: with Aripiprazole I type crystallite, sodium carboxymethylstarch, microcrystalline Cellulose and lactose mix homogeneously, add the polyvidone dilute alcohol solution, mix, pelletize, oven dry is sieved, and adds sodium stearyl fumarate and Pulvis Talci, mix homogeneously, tabletting.
Aripiprazole I type crystallite capsule
Prescription
Aripiprazole (I type crystallite) 5g
Lactose 80g
Microcrystalline Cellulose 30g
Starch 30g
30 POVIDONE K 30 BP/USP-30 2g
Carboxymethylstach sodium 1.8g
Magnesium stearate 1g
Colloidal silica 0.2g
1000 of 150g
Preparation:, add magnesium stearate and colloidal silica mix homogeneously with Aripiprazole I type crystallite, starch, lactose, microcrystalline Cellulose, polyvidone and carboxymethylstach sodium mix homogeneously.Encapsulated, make capsule.
Embodiment 6
Aripiprazole I type crystallite capsule
Prescription
Aripiprazole (I type crystallite) 5g
Lactose 80g
Microcrystalline Cellulose 30g
Pregelatinized Starch 30g
30 POVIDONE K 30 BP/USP-30 2g
Carboxymethylstach sodium 2g
Sodium stearyl fumarate 1g
1000 of 150g
Preparation:, add the sodium stearyl fumarate mix homogeneously with Aripiprazole I type crystallite, pregelatinized Starch, lactose, microcrystalline Cellulose, polyvidone and carboxymethylstach sodium mix homogeneously.Encapsulated, make capsule.
Embodiment 7
Aripiprazole I type microwafer
Prescription:
Aripiprazole (I type crystallite) 5g
Lactose 77g
Microcrystalline Cellulose 30g
Carboxymethylstach sodium 3g
30 POVIDONE K 30 BP/USP-30 1.7g
Polyvinylpolypyrrolidone 2g
Magnesium stearate 0.8g
Colloidal silica 0.5g
1000 of 120g
Preparation: with lactose, microcrystalline Cellulose and sodium carboxymethylstarch, mix homogeneously, add the polyvidone dilute alcohol solution, mixing granulation, oven dry is sieved, and adds Aripiprazole I type crystallite, polyvinylpolypyrrolidone, colloidal silica and magnesium stearate, mix homogeneously, tabletting.
Determination of dissolution rate (1)
Get the sheet of embodiment 2,4 and reference embodiment gained, according to dissolution method (two appendix XC second methods of Chinese Pharmacopoeia version in 2005), (get sodium lauryl sulphate 5g with sodium lauryl sulphate-sodium-acetate buffer, sodium acetate 2g, add water to 1000ml, adding acetic acid adjust pH to 4.7 again) 500ml is solvent, rotating speed is that per minute 75 changes.Measurement result sees Table 1
Table 1: dissolution data list position: %
Under identical prescription condition, the dissolution of I type microwafer is apparently higher than I type coarse-grain sheet, illustrate that the compositions (tablet) that contains crystallite I is better than containing the compositions (tablet) of coarse-grain I, and the dissolution of the crystallite pharmaceutical composition (sheet) of the embodiment of the invention 4 is more excellent than embodiment 2.
Embodiment 9
Determination of dissolution rate (2)
Get the sheet of embodiment 2,3,4,5,6,7 and reference embodiment gained, adopt relatively mild leaching condition to measure comparison.According to dissolution method (two appendix XC second methods of Chinese Pharmacopoeia version in 2005), 500ml is a solvent with sodium dodecyl sulfate solution (get sodium lauryl sulphate 3g, add water to 1000ml), and rotating speed is that per minute 75 changes.Measurement result sees Table 2
Table 2: dissolution data table
Unit: %
The dissolution of pharmaceutical composition of the present invention (sheet or capsule) is apparently higher than the tablet of reference embodiment, and employing high-load lactose and the embodiment 3,4 of microcrystalline Cellulose prescription and 7 tablet, and the dissolution of capsule obviously is better than embodiment 2, therefore, the dissolution of compositions of the present invention is improved significantly, and can improve the bioavailability and the curative effect of Aripiprazole.
Embodiment 10
Stability test
Sample is packed into and is sealed in the high-density polyethylene bottle, and room temperature is placed.
Content assaying method: with octadecylsilane chemically bonded silica is filler; With methanol-0.1% triethylamine solution (90: 10) is mobile phase; The detection wavelength is 255nm.Number of theoretical plate calculates by the Aripiprazole peak should be not less than 1000.Get 20 of this product, the accurate title, decide, porphyrize, and precision takes by weighing in right amount (being equivalent to Aripiprazole 10mg approximately), put in the 200ml measuring bottle, it is an amount of to add methanol, and ultrasonic jolting made the Aripiprazole dissolving in 15 minutes, put cold, add methanol and be diluted to scale, shake up, filter, precision is measured subsequent filtrate 20 μ l and is injected chromatograph of liquid; Other the Aripiprazole reference substance that is dried to constant weight of learning from else's experience 105 ℃ is an amount of, accurate claim fixed, add dissolve with methanol and quantitatively dilution make the solution that contains 50 μ g among every 1ml, measure with method.Press external standard method with calculated by peak area, promptly.
Dissolution determination method is with embodiment 9.
The measurement result of stability test content and dissolution (45 minutes) sees Table 3.
Table 3: stability data table
The content and the dissolution of pharmaceutical composition of the present invention (sheet or capsule) are all more stable.
Claims (5)
1. a Peroral solid dosage form pharmaceutical composition contains brilliant 1-50mg of Aripiprazole I type and acceptable accessories, and it is characterized in that: the mean diameter of Aripiprazole I type crystalline substance is no more than 50um; This Peroral solid dosage form pharmaceutical composition is a capsule; Described acceptable accessories is selected from one or more in following: diluent, disintegrating agent, binding agent and lubricant;
Described diluent is selected from the following material one or more: lactose, microcrystalline Cellulose, starch, pregelatinized Starch and mannitol;
Described disintegrating agent is selected from the following material one or more: carboxymethylstach sodium, polyvinylpolypyrrolidone and low-substituted hydroxypropyl cellulose or their mixture;
Described binding agent is hypromellose, polyvidone or starch slurry;
Described lubricant is magnesium stearate, sodium stearyl fumarate, Pulvis Talci, colloidal silica or their mixture.
2. compositions as claimed in claim 1, the mean diameter of described Aripiprazole I type crystalline substance is no more than 35um.
3. compositions as claimed in claim 1 is characterized in that the particle size distribution 90% of Aripiprazole I type crystalline substance is not more than 50um.
4. compositions as claimed in claim 1 is characterized in that: described Peroral solid dosage form pharmaceutical composition is become to be grouped into by each of following mass fraction:
Aripiprazole (I type crystallite) 5
Lactose 80
Microcrystalline Cellulose 30
Starch 30
30 POVIDONE K 30 BP/USP-30 2
Carboxymethylstach sodium 1.8
Magnesium stearate 1
Colloidal silica 0.2.
5. compositions as claimed in claim 1 is characterized in that: described Peroral solid dosage form pharmaceutical composition is become to be grouped into by each of following mass fraction:
Aripiprazole (I type crystallite) 5
Lactose 80
Microcrystalline Cellulose 30
Pregelatinized Starch 30
30 POVIDONE K 30 BP/USP-30 2
Carboxymethylstach sodium 2
Sodium stearyl fumarate 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010119171 CN101791287B (en) | 2007-05-28 | 2007-05-28 | Solid oral pharmaceutical composition containing aripiprazole microcrystal |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010119171 CN101791287B (en) | 2007-05-28 | 2007-05-28 | Solid oral pharmaceutical composition containing aripiprazole microcrystal |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100413235A Division CN101066267B (en) | 2007-05-28 | 2007-05-28 | Solid oral medicine composition containing aripiprazole microcrystal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101791287A true CN101791287A (en) | 2010-08-04 |
| CN101791287B CN101791287B (en) | 2012-05-23 |
Family
ID=42584348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010119171 Active CN101791287B (en) | 2007-05-28 | 2007-05-28 | Solid oral pharmaceutical composition containing aripiprazole microcrystal |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101791287B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117903050A (en) * | 2024-03-15 | 2024-04-19 | 中国药科大学 | Aripiprazole cocrystal and its pharmaceutical composition and application |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2600542A1 (en) * | 2005-03-17 | 2006-09-21 | Synthon B.V. | Pharmaceutical tablets of crystalline type ii aripiprazole |
-
2007
- 2007-05-28 CN CN 201010119171 patent/CN101791287B/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117903050A (en) * | 2024-03-15 | 2024-04-19 | 中国药科大学 | Aripiprazole cocrystal and its pharmaceutical composition and application |
| CN117903050B (en) * | 2024-03-15 | 2024-05-17 | 中国药科大学 | Aripiprazole cocrystal and its pharmaceutical composition and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101791287B (en) | 2012-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105640890A (en) | Sparingly soluble active component particle, particle preparation and preparation method thereof | |
| CN114796222B (en) | Coated granules, solid dispersions and formulations containing vortioxetine hydrobromide for oral taste masking | |
| US11396558B2 (en) | Hypromellose acetate succinate powder excellent in dissolved state and production method thereof, and production methods for composition for solid dispersion, coating composition, drug-containing particle, and solid | |
| CN101184489A (en) | pharmaceutical composition | |
| NZ539277A (en) | Pharmaceutical product comprising a therapeutically active agent together with a pharmaceutical excipient for use with poorly water-soluble therapeutically active agents | |
| WO2020249001A1 (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
| TWI293883B (en) | Pharmaceutical composition | |
| CN104650091A (en) | Micronization and crystal form of ticagrelor and preparation method and pharmaceutical application of crystal form of ticagrelor | |
| JP2019142927A (en) | Pharmaceutical dosage forms | |
| CN101066267B (en) | Solid oral medicine composition containing aripiprazole microcrystal | |
| CN106619520A (en) | Dry suspension of sodium dexlansoprazole and preparation method of dry suspension | |
| MX2007005427A (en) | Solid dispersion composition of pranlukast with improved bioavailibility and the method of preparing the solid dispersion. | |
| CN105732517A (en) | Medicine preparation containing 5-fluorouracil drug eutectic with nicotinamide as precursor and preparation method of medicine preparation | |
| WO2012088992A1 (en) | Process for preparing solid medicine preparation and solid medicine preparation therefrom | |
| CN101791287B (en) | Solid oral pharmaceutical composition containing aripiprazole microcrystal | |
| CN104721827A (en) | Insoluble antifungal medicament solid dispersion and preparation method thereof | |
| CN103007286A (en) | Solid medicine composition of tolvaptan | |
| CN116763748A (en) | A pharmaceutical oral preparation of Brivaracetam and its preparation method | |
| CN115137705A (en) | Indobufen tablet | |
| CN103768068B (en) | A kind of Bosentan pharmaceutical composition | |
| CN109700773B (en) | Ticagrelor preparation composition and preparation method thereof | |
| CN101491523A (en) | Combination containing micronized gliquidone | |
| CN113116833B (en) | Bilastine tablet and preparation method thereof | |
| CN101129370A (en) | Rimonabant or its salt dispersion patch capable of using in medicine and method of producing the same | |
| CN116492305A (en) | Loflupridine hydrochloride tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 400061 No. 565, Tu Shan Road, Nan'an District, Chongqing Patentee after: Chongqing Pharmaceutical Research Institute Co., Ltd. Patentee after: Shanghai Chinese Medicine Pharmaceutical Co. Ltd. Address before: 400061 No. 565, Tu Shan Road, Nan'an District, Chongqing Patentee before: Chongqing Pharmaceutical Research Institute Co., Ltd. Patentee before: Shanghai Zhongxi Pharmaceutical Co., Ltd. |